查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951866

單株抗體療法市場分析及預測（至2035年）：依類型、產品類型、技術、應用、最終使用者、功能、流程、實施類型及發展階段分類

Monoclonal Antibody Therapy Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Functionality, Process, Deployment, Stage
出版日期: | 出版商: Global Insight Services | 英文 397 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

單株抗體療法市場預計將從2024年的1,865億美元成長到2034年的4,975億美元，複合年成長率約為12.4%。單株抗體療法市場涵蓋實驗室合成分子的開發和分銷，這些分子旨在作為替代抗體，恢復或增強免疫系統功能。這些療法針對特定抗原，能夠精準治療癌症、自體免疫疾病和感染疾病等疾病。生物技術的進步、慢性病盛行率的上升以及對個人化醫療投資的增加是推動市場成長的主要因素，凸顯了治療方法標靶性和有效性不斷提高的趨勢。

受生物技術進步和慢性病發病率上升的推動，單株抗體療法市場正經歷強勁成長。腫瘤治療領域成長最為顯著，這主要得益於對標靶癌症治療需求的不斷成長。在該領域中，專注於查核點抑制劑的細分市場尤其引人注目，展現出巨大的治療潛力。自體免疫疾病領域的成長速度位居第二，其中針對類風濕性關節炎和多發性硬化症的標靶治療方法前景廣闊。感染疾病領域也呈現成長勢頭，特別是針對新冠病毒和愛滋病等病毒感染疾病的單株抗體。雙特異性抗體的創新透過提高特異性和療效，進一步加速了市場成長。此外，市場正朝著人源化和完全人體單株抗體降低免疫抗原性並改善患者預後。持續的研發投入和策略合作有望推動未來的發展，並為治療性介入開闢新的途徑。

市場區隔
類型 鼠源的、嵌合體的、人源化的、人類的、雙特異性的
產品 治療性單株抗體、診斷性單株抗體
科技 融合瘤技術、重組DNA技術、噬菌體展示技術、基因轉殖小鼠
適應症 癌症、自體免疫疾病、感染疾病、心血管疾病、神經系統疾病
最終用戶 醫院、研究機構、生物製藥公司、診斷檢查室
功能 中和作用、細胞毒性、抗發炎作用
過程 上游工程，下游過程
實施表格 內部、外包
步 臨床前、臨床、商業化

單株抗體療法憑藉著創新的定價策略和新產品的大量上市，正迅速佔據顯著的市場佔有率。這一成長得益於生物技術的進步和對個人化醫療日益成長的關注。主要企業正不斷強化產品系列，以因應不同的治療領域，從而促進競爭和創新。價格趨勢持續變化，受到對經濟高效治療方法和具有競爭力的定價模式的需求的影響。單株抗體療法市場的競爭異常激烈，各大製藥公司都在爭奪主導。監管政策，尤其是在北美和歐洲，正在塑造市場動態，並確保安全性和有效性標準的落實。競爭對手的比較分析顯示，策略聯盟和併購已成為企業加強市場滲透的趨勢。法規環境的持續變化影響企業的市場准入和擴大策略。為了因應這些挑戰，各公司正加大研發投入，以期在腫瘤學和自體免疫疾病領域抓住新的機會。

主要趨勢和促進因素：

受生物技術進步和慢性病發病率上升的推動，單株抗體療法市場正經歷強勁成長。一個關鍵趨勢是單株抗體在腫瘤領域的應用日益廣泛。這種透過針對特定癌細胞來提高療效的精準醫療方法備受關注，並顯著擴大了市場規模。另一個趨勢是生物相似藥的開發，它們是品牌單株抗體的更經濟實惠的替代品。這為新興市場帶來了新的機遇，先前成本限制了這些療法的普及。此外，監管機構正在簡化生物相似藥的核准流程，進一步加速了市場成長。抗體工程技術的創新也推動了市場發展，使得開發更有效、更安全的治療方法成為可能。此外，製藥公司和生技公司之間的合作正在促進研發活動，並推動新型單株抗體的問世。此類合作對於滿足各個治療領域尚未滿足的需求至關重要，並有助於擴大市場格局。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 小鼠來源
    • 嵌合體體
    • 人性化
    • 人類
    • 雙特異性抗體
  • 市場規模及預測：依產品分類
    • 治療性單株抗體
    • 診斷用單株抗體
  • 市場規模及預測：依技術分類
    • 融合瘤技術
    • 重組DNA技術
    • 噬菌體展示
    • 基因改造小鼠
  • 市場規模及預測：依應用領域分類
    • 癌症
    • 自體免疫疾病
    • 感染疾病
    • 心血管疾病
    • 神經系統疾病
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 研究所
    • 生物製藥公司
    • 診斷檢查室
  • 市場規模及預測：依功能分類
    • 中和抗體
    • 細胞毒性
    • 消炎（藥）
  • 市場規模及預測：依製程分類
    • 上游工程
    • 下游工藝
  • 市場規模及預測：依發展狀況
    • 內部開發
    • 外包
  • 市場規模及預測：依發展階段分類
    • 臨床前階段
    • 臨床
    • 商業的

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Genmab
  • Morpho Sys
  • Macro Genics
  • Immuno Gen
  • Xencor
  • Zymeworks
  • Pieris Pharmaceuticals
  • Ab Cellera Biologics
  • Mab Vax Therapeutics
  • Onco Immune
  • Immunomedics
  • Alligator Bioscience
  • Bio Invent International
  • Crescendo Biologics
  • F-star Therapeutics
  • Adimab
  • Harpoon Therapeutics
  • I-Mab Biopharma
  • Cantargia

第9章：關於我們

簡介目錄
Product Code: GIS22022

Monoclonal Antibody Therapy Market is anticipated to expand from $186.5 billion in 2024 to $497.5 billion by 2034, growing at a CAGR of approximately 12.4%. The Monoclonal Antibody Therapy Market encompasses the development and distribution of lab-engineered molecules designed to serve as substitute antibodies, restoring or enhancing immune system function. These therapies target specific antigens, offering precision in treating diseases such as cancer, autoimmune disorders, and infectious diseases. The market is driven by advancements in biotechnology, increasing prevalence of chronic diseases, and growing investment in personalized medicine, underscoring a trend towards more targeted and effective treatment modalities.

The Monoclonal Antibody Therapy Market is experiencing robust growth, fueled by advancements in biotechnology and increasing prevalence of chronic diseases. The oncology segment is the top-performing area, driven by the rising demand for targeted cancer treatments. Within this segment, the sub-segment focusing on checkpoint inhibitors is particularly noteworthy, offering significant therapeutic potential. The autoimmune disorders segment emerges as the second highest-performing area, with therapies targeting rheumatoid arthritis and multiple sclerosis showing strong promise. The infectious diseases segment is also gaining momentum, especially with monoclonal antibodies targeting viral infections such as COVID-19 and HIV. Innovations in bispecific antibodies are further propelling market growth, offering enhanced specificity and efficacy. The market is also witnessing a shift towards humanized and fully human monoclonal antibodies, reducing immunogenicity and improving patient outcomes. Ongoing research and development, coupled with strategic partnerships, are anticipated to drive future advancements and open new avenues for therapeutic interventions.

Market Segmentation
TypeMurine, Chimeric, Humanized, Human, Bispecific
ProductTherapeutic Monoclonal Antibodies, Diagnostic Monoclonal Antibodies
TechnologyHybridoma Technology, Recombinant DNA Technology, Phage Display, Transgenic Mice
ApplicationCancer, Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases, Neurological Diseases
End UserHospitals, Research Institutes, Biopharmaceutical Companies, Diagnostic Laboratories
FunctionalityNeutralizing, Cytotoxic, Anti-inflammatory
ProcessUpstream Processing, Downstream Processing
DeploymentIn-house, Outsourced
StagePreclinical, Clinical, Commercial

Monoclonal antibody therapy is gaining traction, with significant market share attributed to innovative pricing strategies and a surge in new product launches. This growth is fueled by advancements in biotechnology and a heightened focus on personalized medicine. Key players are enhancing their portfolios to cater to diverse therapeutic areas, driving competition and innovation. The pricing landscape remains dynamic, influenced by the need for cost-effective treatments and competitive pricing models. Competition in the monoclonal antibody therapy market is fierce, with major pharmaceutical companies vying for dominance. Regulatory influences, particularly in North America and Europe, shape market dynamics, ensuring safety and efficacy standards are met. Benchmarking against competitors reveals a trend toward strategic partnerships and mergers, enhancing market penetration. The regulatory environment continues to evolve, impacting market entry and expansion strategies. Companies are navigating these challenges by investing in research and development, seeking to capitalize on emerging opportunities in oncology and autoimmune diseases.

Geographical Overview:

The Monoclonal Antibody Therapy Market is witnessing robust growth across various regions, each presenting unique opportunities. North America remains at the forefront, driven by advanced healthcare infrastructure and substantial investment in biopharmaceutical research. The region's strong focus on innovative therapies and a supportive regulatory environment further bolster its market position. Europe follows closely, with significant investments in biotechnology and a well-established healthcare system. The region's emphasis on personalized medicine and strong collaboration between academia and industry enhance its market potential. In Asia Pacific, rapid growth is fueled by increasing healthcare expenditure and rising prevalence of chronic diseases. Emerging economies like China and India are investing heavily in biopharmaceuticals, creating new growth pockets. Latin America and the Middle East & Africa are emerging markets with increasing potential. In Latin America, growing healthcare investments and improving access to advanced therapies are driving market expansion. Similarly, the Middle East & Africa are recognizing the importance of monoclonal antibody therapies in addressing unmet medical needs and fostering healthcare innovation.

The global monoclonal antibody therapy market is increasingly influenced by tariffs, geopolitical risks, and evolving supply chain dynamics. Japan and South Korea, traditionally reliant on Western biopharmaceutical imports, are investing in domestic production capabilities to mitigate tariff impacts and ensure supply chain resilience. China is accelerating its innovation in biologics, spurred by geopolitical tensions and export restrictions, while Taiwan leverages its advanced manufacturing expertise to remain a pivotal player. Globally, the market is expanding, driven by rising demand for targeted therapies. By 2035, the market is expected to witness robust growth, contingent on geopolitical stability and diversified supply chains. Middle East conflicts, while indirectly affecting the market, could influence energy prices, thereby impacting production costs and logistics within the global supply chain.

Key Trends and Drivers:

The monoclonal antibody therapy market is experiencing robust growth, driven by advancements in biotechnology and rising prevalence of chronic diseases. A key trend is the increasing adoption of monoclonal antibodies in oncology, where they are used to target specific cancer cells, enhancing treatment efficacy. This precision medicine approach is gaining traction, leading to significant market expansion. Another trend is the development of biosimilars, which are more affordable alternatives to branded monoclonal antibodies. This is opening up new opportunities in emerging markets, where cost constraints have previously limited access to these therapies. Additionally, regulatory bodies are streamlining approval processes for biosimilars, further accelerating market growth. The market is also being driven by technological innovations in antibody engineering, enabling the creation of more potent and safer therapies. Moreover, partnerships between pharmaceutical companies and biotech firms are fostering research and development initiatives, leading to the introduction of novel monoclonal antibodies. These collaborations are crucial in addressing the unmet needs in various therapeutic areas, thus expanding the market landscape.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Functionality
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Murine
    • 4.1.2 Chimeric
    • 4.1.3 Humanized
    • 4.1.4 Human
    • 4.1.5 Bispecific
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutic Monoclonal Antibodies
    • 4.2.2 Diagnostic Monoclonal Antibodies
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Hybridoma Technology
    • 4.3.2 Recombinant DNA Technology
    • 4.3.3 Phage Display
    • 4.3.4 Transgenic Mice
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Cancer
    • 4.4.2 Autoimmune Diseases
    • 4.4.3 Infectious Diseases
    • 4.4.4 Cardiovascular Diseases
    • 4.4.5 Neurological Diseases
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Research Institutes
    • 4.5.3 Biopharmaceutical Companies
    • 4.5.4 Diagnostic Laboratories
  • 4.6 Market Size & Forecast by Functionality (2020-2035)
    • 4.6.1 Neutralizing
    • 4.6.2 Cytotoxic
    • 4.6.3 Anti-inflammatory
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Upstream Processing
    • 4.7.2 Downstream Processing
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 In-house
    • 4.8.2 Outsourced
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Preclinical
    • 4.9.2 Clinical
    • 4.9.3 Commercial

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Functionality
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Functionality
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Functionality
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Functionality
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Functionality
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Functionality
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Functionality
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Functionality
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Functionality
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Functionality
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Functionality
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Functionality
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Functionality
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Functionality
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Functionality
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Functionality
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Functionality
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Functionality
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Functionality
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Functionality
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Functionality
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Functionality
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Functionality
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Functionality
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Genmab
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Morpho Sys
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Macro Genics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Immuno Gen
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Xencor
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Zymeworks
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Pieris Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Ab Cellera Biologics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Mab Vax Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Onco Immune
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Immunomedics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Alligator Bioscience
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Bio Invent International
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Crescendo Biologics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 F-star Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Adimab
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Harpoon Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 I- Mab Biopharma
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Cantargia
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us